Denali Therapeutics (DNLI) Shares Outstanding (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Shares Outstanding data on file, last reported at $158.7 million in Q1 2026.

• Quarterly Shares Outstanding rose 9.23% year-over-year to $158.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $158.7 million (up 9.23% YoY) and the FY2025 annual result came in at $156.2 million, up 8.29% from the prior year.
• Shares Outstanding advanced to $158.7 million in Q1 2026 per DNLI's latest filing, from $156.2 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $158.7 million in Q1 2026 and bottomed at $122.9 million in Q1 2022.
• The 5-year median for Shares Outstanding is $142.5 million (2024), against an average of $140.1 million.
• The widest annual swing landed in 2022, when Shares Outstanding rose 1.34%; it then gained 11.53% in 2023.
• Tracing DNLI's Shares Outstanding over 5 years: stood at $136.0 million in 2022, then rose by 1.78% to $138.4 million in 2023, then climbed by 4.22% to $144.2 million in 2024, then advanced by 8.29% to $156.2 million in 2025, then rose by 1.58% to $158.7 million in 2026.
• Per Business Quant, the three latest DNLI Shares Outstanding figures stand at $158.7 million (Q1 2026), $156.2 million (Q4 2025), and $146.6 million (Q3 2025).

Peer Comparison